Back to rankings

Novanta Inc. (NOVT)

Overvalued
TechnologyScientific & Technical InstrumentsUnited States

Fundamental

55

Price

$142.19

Market Cap

$5.38B

Part 1 · What the company is worth

Overview

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on September 19, 2026 with claude-haiku-4-5 — shared with all users

P/E: 69.9Score: 68Market cap: $55.31B

Named by Novanta as a major Photonics competitor: it supplies the same OEM customers with laser sources, optics and beam-delivery subsystems for industrial processing and medical devices.

SCANLAB GmbHNot tracked

Named by Novanta as a major Photonics competitor: both sell galvanometer-based laser beam-steering scan heads to the same industrial and medical laser-system builders.

OMRON Corporation (オムロン株式会社)6645

Novanta names Omron Microscan Systems as a major Vision competitor: the two compete for the same factory-automation and medical-device OEMs buying machine vision and barcode reading subsystems.

Renishaw plcRSW

Named by Novanta as a major Precision Motion competitor: both sell optical encoders and precision position-feedback devices to machine-tool, semiconductor and medical equipment makers.

Barco NVBAR

Named by Novanta as a major Vision competitor: Barco's healthcare visualization business competes directly with Novanta's surgical and diagnostic display systems sold to medical OEMs and hospitals.

Physik Instrumente (PI) SE & Co. KGNot tracked

Named by Novanta as a major Precision Motion competitor: both supply precision positioning stages and motion subsystems to the same photonics, semiconductor and life-science instrument builders.

Balance Sheet & Liquidity

Revenue

$1.03B

Trailing 12 months (through 7/3/2026)

Net Income

$62M

Trailing 12 months (through 7/3/2026)

Free Cash Flow

$48M

Total Equity

$1.31B

Total Liabilities

$493M

Current Ratio

4.57

Interest Coverage

-

Debt/EBITDA

1.83

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

General caseOvervalued

Fair Value

$89.83

Current Price

$142.19

Margin of Safety

-58.3%

Fair Value Range

$58.39 - $121.27

Spread across the valuation methods used, not a statistically calibrated confidence interval.

Estimation Methods

Analyst price target:$194.50
Discounted cash flow (DCF):$34.60
Earnings multiple (P/E):$54.22
Graham growth formula:$20.89
Earnings power value (EPV):$12.62
Justified P/B:$7.67
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:$48.98
Mid-cycle earnings:$63.07
Revenue multiple:$127.68
Analyst Consensus:Strong Buy (8B / 1H / 0S)
Last Earnings Surprise:+5.13%

Valuation Metrics

P/E Ratio

90.57

ROE

4.1%

P/B Ratio

3.33

P/FCF

47.05

Gross Margin

44.5%

ROIC

3.9%

Profitability Radar

Value Creation (Economic Moat)

ROIC

3.9%

WACC

13.3%

ROIC − WACC

-9.5 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamental Analysis Criteria

Passed (16)

  • EPS shows upward trend
  • Price CAGR 21.27%
  • Gross Margin 44.5%
  • Debt/Equity ratio
  • Operating Margin 9.0%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • Revenue Growth 5Y 10.7%
  • Analyst Consensus 89% Buy
  • Earnings Surprise avg 3.3%
  • Earnings Quality (OCF/NI) 2.17
  • Share Dilution 1.1%
  • Piotroski F-Score 5/9

Failed (9)

  • ROIC 3.8%
  • P/FCF 47.05
  • P/B Ratio 3.33
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 4.9%
  • PEG Ratio 26.26
  • Net Margin Trend 6.0% vs 6.4%

Unavailable (2)

  • Dividend Payout NaN%
  • Interest Coverage

Piotroski F-Score

5/9

Mixed signals: some areas need attention

score
criteria

Earnings Quality

2.17

High quality: earnings backed by cash

Share Dilution

1.1%

Share count is stable

Institutional Holdings

Governance

Executive Team

NameTitleAge
Mr. Matthijs GlastraCEO & Chairman of the Board56
Mr. Robert J. BuckleyChief Financial Officer51
Mr. Alexander ManganielloGeneral Counsel & Corporate Secretary58
Mr. Charles G. RavettoCo-Chief Operating Officer of Automation Enabling Technologies54
Mr. John LesicaCo-Chief Operating Officer of Medical Solutions49
Mr. John Joseph Burke IIChief Accounting Officer & Corporate Controller43
Ms. Sarah BetadamChief Information Officer & Chief Information Security Officer-
Ms. Nissia SabriSenior Vice President of Corporate Development-
Mr. Liam WestonChief Human Resources Officer-
Mr. Heinrich DreyerGroup President of Medical Solutions-

Audit Risk

2

Board Risk

4

Compensation Risk

4

Shareholder Rights Risk

2

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Documents

  • Annual Report (10-K)

    A yearly overview of the business, its financial results, and the risks it faces.

    Filed on 2026-02-23

    View document
  • Quarterly Report (10-Q)

    A snapshot of financial performance for the most recent three-month period.

    Filed on 2026-08-05

    View document
  • Current Report (8-K)

    An announcement of a major event, such as a leadership change or big news.

    Filed on 2026-08-05

    View document

via SEC EDGAR

Income History

via SEC EDGAR

Latest News

Recent headlines for NOVT, sourced from Markets Gazette.

  • 3/4/2026POSITIVE
    Novanta Stock Has Underperformed This Past Year, but One Investor Just Made a $36 Million Bet on Shares

    Despite underperforming over the past year, Novanta Inc. (NOVT) has attracted a significant bet from an investor who purchased $36 million worth of shares. This bold move suggests strong conviction in the company's future recovery and growth potential. Novanta designs photonics and precision motion solutions for OEMs in medical and industrial markets globally. While the stock has lagged, this substantial investment could signal a turning point, indicating that the company's underlying value is underestimated by the market and may lead to a positive re-evaluation.

  • 2/24/2026NEUTRAL
    Novanta (NOVT) Q4 2025 Earnings Call Transcript

    Markets Gazette notes the release of the earnings call transcript for Novanta Inc. (NOVT) concerning its fourth-quarter 2025 results. While specific financial figures and future projections have not yet been made public or analyzed herein, the availability of this document is a key event for investors. Earnings call transcripts provide direct insights into company performance, management strategies, challenges faced, and growth prospects, often revealing the tone and expectations of leadership. Shareholders and analysts will closely monitor this document for any implicit or explicit signals that could influence the stock's value in the short to medium term. The current lack of specific content necessitates a cautious approach, but the transcript remains a crucial resource for due diligence.

  • 2/23/2026NEUTRAL
    A Preview Of Novanta's Earnings

    The Markets Gazette notes that investor focus is turning to Novanta Inc. ahead of its upcoming earnings release. The article, while providing no specific data, serves as a calendar marker for a key event that could define the stock's short-term trajectory. Analysts and the market are awaiting crucial figures such as revenue, earnings per share (EPS), and, most importantly, forward-looking guidance for the coming quarters. The stock's reaction will largely depend on how the actual results compare against consensus estimates. Until the official announcement, traders are likely to maintain a cautious stance, with trading volumes potentially increasing closer to the release date, signaling heightened anticipation.

  • 2/22/2026NEGATIVE
    Is Novanta Stock a Buy or Sell After Its CEO Dumped 6,500 Shares?

    Novanta Inc., a leader in photonics and precision motion solutions for OEMs, has experienced notable insider selling. The CEO recently offloaded 6,500 shares, a move that could signal diminished confidence in the company's future performance from top management. While Novanta operates in promising tech sectors, this insider action might concern investors, suggesting the current stock price could be considered high or that potential challenges lie ahead not yet fully reflected in the market. Investors should closely watch upcoming financial reports and operational performance to assess the impact of this sale.

via Markets Gazette